ArticleEmerging infectious diseases2018
Multilocus Sequence Typing of Mycoplasma pneumoniae, Japan, 2002-2016.
Article in Emerging infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.Emerging infectious diseases · 2020Pooled it
- High-Risk CCL14 lineage drives severe Mycoplasma pneumoniae pneumonia in children: a study in central China.Clinical and experimental pediatrics · 2026Article
- Molecular insights into macrolide resistant Mycoplasma pneumoniae isolates from outpatient clinics in Tehran, Iran.Scientific reports · 2026Article
- Population structure reveals clade- and region-specific dissemination of macrolide-resistantFrontiers in cellular and infection microbiology · 2026Article
- Growing Threat of Macrolide-ResistantJournal of Korean medical science · 2025Review
- Increased macrolide resistance rate ofFrontiers in microbiology · 2024Article
- The molecular characteristics, diagnosis, and treatment of macrolide-resistantFrontiers in pediatrics · 2023Review
- Association of Tandem Repeat Number Variabilities in Subunit S of the Type I Restriction-Modification System with Macrolide Resistance inJournal of clinical medicine · 2022Article
- Consideration in treatment decisions for refractory Mycoplasma pneumoniae pneumonia.Clinical and experimental pediatrics · 2021Article
- Sequence Type Changes Associated with Decreasing Macrolide-Resistant Mycoplasma pneumoniae, Japan.Emerging infectious diseases · 2020Article
- Dynamic change ofTranslational pediatrics · 2020Article
- Comparative genomics of Mycoplasma pneumoniae isolated from children with pneumonia: South Korea, 2010-2016.BMC genomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Japan, Mycoplasma pneumoniae resistance to macrolides is high. To compare sequence types (STs) of susceptible and resistant isolates, we performed multilocus sequence typing for 417 isolates obtained in Japan during 2002-2016. The most prevalent ST overall was ST3, for macrolide-resistant was ST19, and for macrolide-susceptible were ST14 and ST7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.